Probiotics and Non Alcoholic Steatohepatitis (NASH)
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 38
- 试验地点
- 1
- 主要终点
- Lactulose breath test
研究概览
简要总结
Nonalcoholic Fatty Liver Disease (NAFLD) has been suggested to be the most common cause of chronic liver disease in the general population in the Western World. In advanced stages of NAFLD, steatohepatitis (NASH) develops characterized by: steatosis, inflammation, and fibrosis progressing to cirrhosis in some patients. The knowledge of the role of small intestinal bacterial overgrowth (SIBO) in the pathogenesis of NASH has led to the proposal of probiotics as a therapeutic strategy for this disorder.
详细描述
Probiotics may interfere with the development of NASH by several mechanisms. Data from an uncontrolled clinical trial in NASH patients show promising results, with improvement of liver enzymes in treated patients.
RESEARCH GOALS:
A. To assess the degree of SIBO in NAFLD patients vs. healthy controls. B. To evaluate the effect of probiotics vs. placebo on SIBO in NAFLD patients. C. To evaluate the effect of probiotics vs. placebo on disease severity (inflammation, steatosis, and fibrosis) in NAFLD patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Controls- healthy volunteers, male and female, above 18 years.
- •NAFLD group - patients with histological proven NAFLD, male and female, above 18 years.
排除标准
- •those who will be found to have fatty liver in abdominal ultra sound
- •any participant who will take antibiotics for any indication for more than 1 week during the study period or before recruitment to the study
- •any participant who had lost more than 10% of baseline body weight during the study period.
- •NAFLD group
- •those who will be found to have any concomitant liver disease (i.e., HBV/HCV/HIV/EBV/CMV infection
- •autoimmune hepatitis
- •metabolic liver disease: Wilson's disease, cholestatic liver disease: PBC/PSC, etc.)
- •any participant who will take antibiotics for any indication for more than 1 week during the study period or before recruitment to the study
- •any participant who had lost more than 10% of baseline body weight during the study period
研究组 & 干预措施
OSA and NAFLD patients using CPAP
OSA and NAFLD patients using CPAP being followed for 6 months.
干预措施: BioFemale (Dietary Supplement)
control
OSA and NAFLD patients not using CPAP being followed for 6 months.
结局指标
主要结局
Lactulose breath test
时间窗: Measurement at recruitment (0) and at the end of treatment period (6 mo)
SIBO in NASH patients in both treated groups (probiotics treated versus placebo treated) will be evaluated by lactulose breath test
时间窗: Recruitment period of 6 months and 6 months of treatment after each recruitment
次要结局
- FIBROMAX tests will assess severity of NAFLD in patients' group prior to treatment and post treatment(At recruitment to the study (0) and at the end of treatment (6 mo))
- Fibromax test for the evaluation of NAFLD severity(At the recruitment (0) and at the end of treatment (6 mo))